New imaging agent aims to spot Hard-to-Find tumors
NCT ID NCT06735560
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing a new radioactive tracer called 89Zr-TLX250, which targets a protein (CAIX) found on certain tumor cells. The goal is to see if PET-CT scans using this tracer can detect more tumor lesions in people with liver cancer, bile duct cancer, or neuroendocrine tumors compared to standard imaging. The study will enroll 60 adults and also monitor for any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 89Zr-TLX250 (a radioactive tracer for PET imaging)
- What this could lead to
- If successful, this could provide a more accurate imaging method for detecting these tumors, potentially guiding better treatment decisions.
- What could go wrong
- This is a small, early pilot study with only 60 participants. The tracer may not detect all tumors as hoped, and there are risks from radiation exposure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HP - Site de Beaujon
NOT_YET_RECRUITINGParis, France
-
CHU de Nantes
RECRUITINGNantes, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spirulina's secret protein may shield the liver during surgery
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- AI-Powered surveillance may outsmart liver cancer recurrence